 As secondary outcomes, reduction of left ventricle LV mass and carotid intima-media thickness will be evaluated as markers of preclinical cardiovascular disease, under the hypothesis that improvement of end-organ damage under diuretic-based treatment will not be different from the treatment based on other antihypertensive medications equivalence. The reduction of the ESHESC risk-score will also be evaluated, under the same equivalence hypothesis. Sample size was primarily estimated for the primary outcome, but afterward tested on power also on secondary outcomes. See Annex for details 